This trial is studying the side effects and best dosage of two drugs, pazopanib hydrochloride and bevacizumab, to treat patients with metastatic kidney cancer that has not been previously treated. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Bevacizumab is a monoclonal antibody that can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor
- Clear Cell Renal Cell Carcinoma
- Stage IV Renal Cell Carcinoma
2 Primary · 4 Secondary · Reporting Duration: At 12 months
1 Treatment Group
Treatment (pazopanib hydrochloride and bevacizumab)
1 of 1
51 Total Participants · 1 Treatment Group
Primary Treatment: Pazopanib Hydrochloride · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the scientific community's previous experience with Pazopanib Hydrochloride?
"Pazopanib Hydrochloride was first studied in the year 2004 at Memoral Sloan Kettering Basking Ridge (Follow Up Only). As of now, there have been a total of 1719 completed clinical trials. Additionally, there are currently 401 live studies, with a considerable amount of these studies taking place in Pittsburgh, Pennsylvania." - Anonymous Online Contributor
Are there several inpatient facilities conducting this research project in North America?
"There are a total of 5 sites where this clinical trial is taking place. The University of Pittsburgh Cancer Institute (UPCI) in Pittsburgh, the Medical College of Wisconsin in Milwaukee, and the Karamanos Cancer Institute in Detroit are 3 of these sites." - Anonymous Online Contributor
What purpose does Pazopanib Hydrochloride usually serve?
"Pazopanib Hydrochloride is most often used as a treatment for malignant neoplasms. However, this medication can also be effective in managing recurrent platinum sensitive primary peritoneal cancer, advanced thyroid cancer, and stage iv epithelial ovarian cancer that has had initial surgical resection." - Anonymous Online Contributor